Cargando…

Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study

METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Lianghe, Wei, Jing, Ye, Jun, Zhang, Chuanmeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952178/
https://www.ncbi.nlm.nih.gov/pubmed/33747258
http://dx.doi.org/10.1155/2021/9508702
_version_ 1783663669670838272
author Jiao, Lianghe
Wei, Jing
Ye, Jun
Zhang, Chuanmeng
author_facet Jiao, Lianghe
Wei, Jing
Ye, Jun
Zhang, Chuanmeng
author_sort Jiao, Lianghe
collection PubMed
description METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. RESULTS: Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001). CONCLUSIONS: PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.
format Online
Article
Text
id pubmed-7952178
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-79521782021-03-19 Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study Jiao, Lianghe Wei, Jing Ye, Jun Zhang, Chuanmeng Dis Markers Research Article METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. RESULTS: Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001). CONCLUSIONS: PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy. Hindawi 2021-03-03 /pmc/articles/PMC7952178/ /pubmed/33747258 http://dx.doi.org/10.1155/2021/9508702 Text en Copyright © 2021 Lianghe Jiao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jiao, Lianghe
Wei, Jing
Ye, Jun
Zhang, Chuanmeng
Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
title Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
title_full Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
title_fullStr Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
title_full_unstemmed Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
title_short Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
title_sort prognostic value of peroxiredoxin-1 expression in patients with solid tumors: a meta-analysis of cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952178/
https://www.ncbi.nlm.nih.gov/pubmed/33747258
http://dx.doi.org/10.1155/2021/9508702
work_keys_str_mv AT jiaolianghe prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy
AT weijing prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy
AT yejun prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy
AT zhangchuanmeng prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy